In brain research, be it basic or clinical, neurons have long hogged the limelight. But at the 2023 European Meeting on Glial Cells in Health and Disease, neurons take a back seat to glia – cell types that have often been described as support cells and treated as an afterthought, but that play critical roles in all aspects of brain function, including information processing. Read More
A chance discovery has led to a new class of antibiotics with multiple arms that interacted with the cell wall of gram-positive bacteria, inhibiting their assembly and disarming them. “It was an accidental discovery. We were using it to stain cells. We also were running evaluations of antibiotics. One of my former students came to me and said: ‘I think we have discovered something that is quite potent as an antibiotic,’” the senior author Xingyu Jiang told BioWorld. Read More
A new academic and commercial collaboration between The Institute of Cancer Research, the Bellvitge Biomedical Research Institute (Institut d’Investigació Biomèdica de Bellvitge, IDIBELL) and Vivan Therapeutics (My Personal Therapeutics Ltd.) seeks to create cancer drugs less prone to drug resistance, with a particular focus on drugs that could target KRAS. Read More
3M Innovative Properties Co. has synthesized immune response modifiers (IRMs) and their conjugates reported to be useful for the treatment of cancer and viral infections. Read More
Delix Therapeutics Inc. has identified pyrrolidine psychoplastogens acting as 5-HT2A receptor modulators reported to be useful for the treatment of neurodegeneration, substance abuse and dependence, impulse control, mood, sleep, anxiety, eating and personality disorders, among others. Read More
Raya Therapeutic Inc. has entered into an early-stage R&D collaboration with Argenx SE to evaluate combinations of Raya’s pipeline of targeted small molecules with a potentially complementary product from Argenx. Read More
Researchers from Washington University in St. Louis and affiliated organizations have provided details on the discovery and preclinical evaluation of [64Cu]NODAGA-PEG4-SL-022-GGS, a novel small peptide imaging agent for evaluating CD38 expression. Read More
Sato Pharmaceutical Co. Ltd. has divulged azaindole derivatives acting as hematopoietic prostaglandin D synthase (HPGDS) inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, asthma, chronic obstructive pulmonary disease, cystic fibrosis, myocardial infarction, rheumatoid arthritis, sarcopenia and thromboangiitis obliterans (Buerger’s disease), among others. Read More
Antibodies against β-2-glycoprotein I (β-2-GPI) play a crucial role in thrombus formation in conditions such as antiphospholipid syndrome (APS). Despite the efficacy of recombinant tissue plasminogen activator (rtPA) in patients with APS, this therapy presents significant limitations, including safety concerns. Read More
Corcept Therapeutics Inc. has described piperazine indazole glucocorticoid receptor (GR) antagonists reported to be useful for the treatment of obesity, Cushing syndrome, Alzheimer’s disease, amyotrophic lateral sclerosis, nonalcoholic steatohepatitis and cancer, among others. Read More
